Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide

Toshio Igaki, Hiroshi Itoh, Shin Ichi Suga, Norio Hama, Yoshihiro Ogawa, Yasato Komatsu, Jun Yamashita, Kentaro Doi, Tae Hwa Chun, Kazuwa Nakao

Research output: Contribution to journalReview article

39 Citations (Scopus)


We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human a-trial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31±1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3±1.3, -4.1±1.0 mmHg) with a significant increase in heart rate (+7.6±2.6 bpm), and exerted significant diuretic and natriuretic activities (+130±80%, +160±100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalHypertension Research
Issue number1
Publication statusPublished - Jan 1 1998
Externally publishedYes


All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this